View Financial HealthST PharmLtd 配当と自社株買い配当金 基準チェック /06ST PharmLtd配当を支払う会社であり、現在の利回りは0.4%です。主要情報0.4%配当利回り-0.2%バイバック利回り総株主利回り0.2%将来の配当利回り0.4%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向15%最近の配当と自社株買いの更新Upcoming Dividend • Mar 23Upcoming dividend of ₩500 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 20 April 2026. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (0.6%).お知らせ • Feb 27ST Pharm Co.,Ltd. announces Annual dividend, payable on April 20, 2026ST Pharm Co.,Ltd. announced Annual dividend of KRW 500.0000 per share payable on April 20, 2026, ex-date on March 30, 2026 and record date on March 31, 2026.Upcoming Dividend • Dec 20Upcoming dividend of ₩500 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 24 April 2025. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.1%).Upcoming Dividend • Dec 20Upcoming dividend of ₩500 per share at 0.8% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 29 April 2024. Payout ratio is on the higher end at 81% but the company is not cash flow positive. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.5%). In line with average of industry peers (0.9%).Upcoming Dividend • Dec 21Upcoming dividend of ₩500 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. Payout ratio is on the higher end at 85% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (0.7%).すべての更新を表示Recent updates分析記事 • Jul 10Should You Be Adding ST PharmLtd (KOSDAQ:237690) To Your Watchlist Today?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Valuation Update With 7 Day Price Move • Jun 08Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩109,500, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩167,043 per share.Buy Or Sell Opportunity • May 28Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to ₩135,400. The fair value is estimated to be ₩173,672, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.9% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings are also forecast to grow by 26% per annum over the same time period.Valuation Update With 7 Day Price Move • May 15Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩131,400, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 57% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩138,802 per share.Major Estimate Revision • Apr 29Consensus EPS estimates increase by 15%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩411.9m to ₩416.9m. EPS estimate increased from ₩3,054 to ₩3,508 per share. Net income forecast to grow 43% next year vs 8.3% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target up from ₩168,249 to ₩183,333. Share price rose 15% to ₩163,400 over the past week.Price Target Changed • Apr 28Price target increased by 9.0% to ₩175,556Up from ₩161,111, the current price target is an average from 9 analysts. New target price is approximately in line with last closing price of ₩168,700. Stock is up 116% over the past year. The company is forecast to post earnings per share of ₩3,508 for next year compared to ₩2,706 last year.Valuation Update With 7 Day Price Move • Apr 27Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩167,500, the stock trades at a forward P/E ratio of 55x. Average forward P/E is 21x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 116% over the past three years.お知らせ • Apr 23ST Pharm Co.,Ltd. to Report Q1, 2026 Results on Apr 27, 2026ST Pharm Co.,Ltd. announced that they will report Q1, 2026 results on Apr 27, 2026Buy Or Sell Opportunity • Apr 06Now 21% undervaluedOver the last 90 days, the stock has risen 8.2% to ₩136,800. The fair value is estimated to be ₩172,076, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.9% over the last 3 years. Earnings per share has grown by 34%. Revenue is forecast to grow by 48% in 2 years. Earnings are forecast to grow by 60% in the next 2 years.分析記事 • Mar 27ST PharmLtd's (KOSDAQ:237690) Earnings Are Of Questionable QualityST Pharm Co.,Ltd. ( KOSDAQ:237690 ) announced strong profits, but the stock was stagnant. Our analysis suggests that...Upcoming Dividend • Mar 23Upcoming dividend of ₩500 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 20 April 2026. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (0.6%).Buy Or Sell Opportunity • Mar 04Now 24% undervaluedOver the last 90 days, the stock has risen 12% to ₩131,500. The fair value is estimated to be ₩172,330, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.3% over the last 3 years. Earnings per share has grown by 31%. Revenue is forecast to grow by 47% in 2 years. Earnings are forecast to grow by 122% in the next 2 years.お知らせ • Feb 28ST Pharm Co.,Ltd., Annual General Meeting, Mar 26, 2026ST Pharm Co.,Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 171, haean-ro, danwon-gu, gyeonggi-do, ansan South Koreaお知らせ • Feb 27ST Pharm Co.,Ltd. announces Annual dividend, payable on April 20, 2026ST Pharm Co.,Ltd. announced Annual dividend of KRW 500.0000 per share payable on April 20, 2026, ex-date on March 30, 2026 and record date on March 31, 2026.Price Target Changed • Feb 14Price target increased by 9.8% to ₩157,000Up from ₩143,000, the current price target is an average from 10 analysts. New target price is 7.0% above last closing price of ₩146,700. Stock is up 74% over the past year. The company is forecast to post earnings per share of ₩2,523 for next year compared to ₩1,780 last year.Price Target Changed • Feb 10Price target increased by 8.8% to ₩149,000Up from ₩137,000, the current price target is an average from 10 analysts. New target price is approximately in line with last closing price of ₩152,400. Stock is up 70% over the past year. The company is forecast to post earnings per share of ₩2,523 for next year compared to ₩1,780 last year.お知らせ • Feb 06ST Pharm Co.,Ltd. to Report Fiscal Year 2025 Results on Feb 09, 2026ST Pharm Co.,Ltd. announced that they will report fiscal year 2025 results at 3:30 PM, Korea Standard Time on Feb 09, 2026分析記事 • Feb 02ST Pharm Co.,Ltd. (KOSDAQ:237690) Stocks Shoot Up 39% But Its P/S Still Looks ReasonableST Pharm Co.,Ltd. ( KOSDAQ:237690 ) shares have continued their recent momentum with a 39% gain in the last month...Price Target Changed • Jan 26Price target increased by 10% to ₩143,000Up from ₩129,500, the current price target is an average from 10 analysts. New target price is approximately in line with last closing price of ₩149,500. Stock is up 71% over the past year. The company is forecast to post earnings per share of ₩2,523 for next year compared to ₩1,780 last year.分析記事 • Jan 24ST PharmLtd (KOSDAQ:237690) Seems To Use Debt Quite SensiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Buy Or Sell Opportunity • Jan 21Now 23% undervaluedOver the last 90 days, the stock has risen 29% to ₩116,900. The fair value is estimated to be ₩152,430, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.3% over the last 3 years. Earnings per share has grown by 31%. Revenue is forecast to grow by 49% in 2 years. Earnings are forecast to grow by 137% in the next 2 years.分析記事 • Dec 30Is There An Opportunity With ST Pharm Co.,Ltd.'s (KOSDAQ:237690) 22% Undervaluation?Key Insights The projected fair value for ST PharmLtd is ₩152,430 based on 2 Stage Free Cash Flow to Equity ST PharmLtd...Buy Or Sell Opportunity • Dec 26Now 21% undervaluedOver the last 90 days, the stock has risen 36% to ₩120,900. The fair value is estimated to be ₩152,430, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.3% over the last 3 years. Earnings per share has grown by 31%. Revenue is forecast to grow by 49% in 2 years. Earnings are forecast to grow by 137% in the next 2 years.分析記事 • Dec 15Earnings Tell The Story For ST Pharm Co.,Ltd. (KOSDAQ:237690) As Its Stock Soars 27%ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) shares have continued their recent momentum with a 27% gain in the last month...Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩117,000, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 57% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩149,224 per share.Price Target Changed • Nov 22Price target increased by 8.2% to ₩126,500Up from ₩116,889, the current price target is an average from 10 analysts. New target price is 27% above last closing price of ₩99,800. Stock is up 20% over the past year. The company is forecast to post earnings per share of ₩2,444 for next year compared to ₩1,780 last year.分析記事 • Oct 29ST Pharm Co.,Ltd.'s (KOSDAQ:237690) Share Price Matching Investor OpinionWhen close to half the companies in Korea have price-to-earnings ratios (or "P/E's") below 14x, you may consider ST...お知らせ • Oct 27ST Pharm Co.,Ltd. to Report Nine Months, 2025 Results on Oct 29, 2025ST Pharm Co.,Ltd. announced that they will report nine months, 2025 results on Oct 29, 2025分析記事 • Sep 11A Look At The Fair Value Of ST Pharm Co.,Ltd. (KOSDAQ:237690)Key Insights ST PharmLtd's estimated fair value is ₩81,102 based on 2 Stage Free Cash Flow to Equity With ₩93,700 share...Buy Or Sell Opportunity • Sep 03Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 28% to ₩98,700. The fair value is estimated to be ₩81,102, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 36%. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 110% in the next 2 years.分析記事 • Aug 26Is ST PharmLtd (KOSDAQ:237690) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Aug 05Here's Why ST PharmLtd (KOSDAQ:237690) Has Caught The Eye Of InvestorsKOSDAQ:A237690 1 Year Share Price vs Fair Value Explore ST PharmLtd's Fair Values from the Community and select yours...Buy Or Sell Opportunity • Jul 22Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 23% to ₩94,300. The fair value is estimated to be ₩77,818, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 89% in the next 2 years.お知らせ • Jul 18ST Pharm Co.,Ltd. to Report First Half, 2025 Final Results on Jul 24, 2025ST Pharm Co.,Ltd. announced that they will report first half, 2025 final results on Jul 24, 2025Buy Or Sell Opportunity • Jul 01Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 16% to ₩84,400. The fair value is estimated to be ₩68,902, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 52% in 2 years. Earnings are forecast to grow by 89% in the next 2 years.分析記事 • Jun 13Shareholders Should Be Pleased With ST Pharm Co.,Ltd.'s (KOSDAQ:237690) PriceST Pharm Co.,Ltd.'s ( KOSDAQ:237690 ) price-to-earnings (or "P/E") ratio of 55.4x might make it look like a strong sell...Buy Or Sell Opportunity • Jun 09Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 9.5% to ₩80,300. The fair value is estimated to be ₩66,340, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 52% in 2 years. Earnings are forecast to grow by 89% in the next 2 years.分析記事 • May 26ST PharmLtd (KOSDAQ:237690) Takes On Some Risk With Its Use Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • May 07Calculating The Intrinsic Value Of ST Pharm Co.,Ltd. (KOSDAQ:237690)Key Insights ST PharmLtd's estimated fair value is ₩66,531 based on 2 Stage Free Cash Flow to Equity Current share...Buy Or Sell Opportunity • Apr 29Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to ₩78,200. The fair value is estimated to be ₩98,270, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 46%. For the next 3 years, revenue is forecast to grow by 20% per annum. Earnings are also forecast to grow by 27% per annum over the same time period.お知らせ • Apr 28ST Pharm Co.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025ST Pharm Co.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩77,500, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 15x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 17% over the past three years.分析記事 • Apr 02ST PharmLtd's (KOSDAQ:237690) Earnings Are Built On Soft FoundationsSolid profit numbers didn't seem to be enough to please ST Pharm Co.,Ltd.'s ( KOSDAQ:237690 ) shareholders. Our...New Risk • Apr 01New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 35% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.お知らせ • Mar 01ST Pharm Co.,Ltd., Annual General Meeting, Mar 31, 2025ST Pharm Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 171, haean-ro, danwon-gu, gyeonggi-do, ansan South KoreaMajor Estimate Revision • Feb 12Consensus EPS estimates fall by 23%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from ₩362.2m to ₩329.5m. EPS estimate also fell from ₩2,579 per share to ₩1,975 per share. Net income forecast to grow 24% next year vs 6.1% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩127,700 unchanged from last update. Share price rose 3.6% to ₩85,800 over the past week.分析記事 • Feb 11Getting In Cheap On ST Pharm Co.,Ltd. (KOSDAQ:237690) Might Be DifficultWith a price-to-earnings (or "P/E") ratio of 58.1x ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) may be sending very bearish...Valuation Update With 7 Day Price Move • Feb 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩93,400, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 20x in the Pharmaceuticals industry in South Korea. Negligible returns to shareholders over past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩41,024 per share.お知らせ • Feb 06ST Pharm Co.,Ltd. to Report Q4, 2024 Results on Feb 10, 2025ST Pharm Co.,Ltd. announced that they will report Q4, 2024 results on Feb 10, 2025分析記事 • Jan 21Does ST PharmLtd (KOSDAQ:237690) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Upcoming Dividend • Dec 20Upcoming dividend of ₩500 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 24 April 2025. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.1%).Valuation Update With 7 Day Price Move • Dec 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩75,600, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 14x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 39% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩61,471 per share.分析記事 • Nov 22Should You Be Adding ST PharmLtd (KOSDAQ:237690) To Your Watchlist Today?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Major Estimate Revision • Nov 05Consensus EPS estimates fall by 14%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩300.6m to ₩296.6m. EPS estimate also fell from ₩2,058 per share to ₩1,769 per share. Net income forecast to grow 100% next year vs 13% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩127,700 unchanged from last update. Share price rose 3.1% to ₩97,600 over the past week.分析記事 • Aug 30ST Pharm Co.,Ltd.'s (KOSDAQ:237690) Shares Climb 29% But Its Business Is Yet to Catch UpThe ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) share price has done very well over the last month, posting an excellent gain...Major Estimate Revision • Aug 20Consensus EPS estimates increase by 17%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from ₩296.6m to ₩311.4m. EPS estimate increased from ₩1,912 to ₩2,236 per share. Net income forecast to grow 101% next year vs 16% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target up from ₩115,778 to ₩119,111. Share price rose 12% to ₩100,300 over the past week.分析記事 • Aug 17Is Now The Time To Put ST PharmLtd (KOSDAQ:237690) On Your Watchlist?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩74,200, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 16x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 32% over the past three years.お知らせ • Jul 23ST Pharm Co.,Ltd. to Report Q2, 2024 Results on Jul 25, 2024ST Pharm Co.,Ltd. announced that they will report Q2, 2024 results on Jul 25, 2024New Risk • May 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Large one-off items impacting financial results.分析記事 • May 09Is ST Pharm Co.,Ltd. (KOSDAQ:237690) Trading At A 41% Discount?Key Insights ST PharmLtd's estimated fair value is ₩157,784 based on 2 Stage Free Cash Flow to Equity Current share...Buy Or Sell Opportunity • May 02Now 23% undervaluedOver the last 90 days, the stock has risen 45% to ₩88,800. The fair value is estimated to be ₩114,797, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 29% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 40% per annum over the same time period.お知らせ • May 01ST Pharm Co.,Ltd. to Report Q1, 2024 Results on May 02, 2024ST Pharm Co.,Ltd. announced that they will report Q1, 2024 results on May 02, 2024分析記事 • Mar 22Why ST PharmLtd's (KOSDAQ:237690) Earnings Are Better Than They SeemST Pharm Co.,Ltd. ( KOSDAQ:237690 ) announced a healthy earnings result recently, and the market rewarded it with a...Reported Earnings • Mar 20Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: EPS: ₩1,041 (up from ₩957 in FY 2022). Revenue: ₩285.0b (up 14% from FY 2022). Net income: ₩19.6b (up 8.8% from FY 2022). Profit margin: 6.9% (down from 7.2% in FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 14%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.分析記事 • Mar 18ST Pharm Co.,Ltd. (KOSDAQ:237690) Stock Rockets 54% As Investors Are Less Pessimistic Than ExpectedThe ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) share price has done very well over the last month, posting an excellent gain...お知らせ • Feb 28ST Pharm Co.,Ltd., Annual General Meeting, Mar 25, 2024ST Pharm Co.,Ltd., Annual General Meeting, Mar 25, 2024, at 09:01 Korea Standard Time. Location: 3F ST Pharm Banwol Campus Innovation Center (171, Haean- ro, Danwon-gu, Ansan-si, Gyeonggi-do) South Korea Agenda: To consider approval of the 16th (consolidated) financial statements, cash dividend of KRW 500 per share; to consider appointment of director; to consider appointment of auditor and to consider other matters.Buy Or Sell Opportunity • Feb 27Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at ₩63,800. The fair value is estimated to be ₩81,265, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 365% in the next 2 years.Major Estimate Revision • Feb 03Consensus EPS estimates increase by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from ₩312.7m to ₩322.1m. EPS estimate increased from ₩1,837 to ₩2,044 per share. Net income forecast to grow 199% next year vs 27% growth forecast for Life Sciences industry in South Korea. Consensus price target of ₩105,000 unchanged from last update. Share price was steady at ₩61,200 over the past week.お知らせ • Feb 01ST Pharm Co.,Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024ST Pharm Co.,Ltd. announced that they will report fiscal year 2023 results on Feb 01, 2024Upcoming Dividend • Dec 20Upcoming dividend of ₩500 per share at 0.8% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 29 April 2024. Payout ratio is on the higher end at 81% but the company is not cash flow positive. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.5%). In line with average of industry peers (0.9%).Major Estimate Revision • Nov 07Consensus EPS estimates fall by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩291.5m to ₩284.2m. EPS estimate also fell from ₩1,376 per share to ₩1,206 per share. Net income forecast to grow 62% next year vs 23% growth forecast for Life Sciences industry in South Korea. Consensus price target down from ₩121,000 to ₩111,818. Share price rose 4.7% to ₩71,200 over the past week.お知らせ • Aug 11ST Pharm Co.,Ltd. announced that it has received KRW 100 billion in fundingOn August 9, 2023, ST Pharm Co.,Ltd. closed the transaction.Reported Earnings • Mar 23Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: ₩957 (up from ₩177 in FY 2021). Revenue: ₩249.3b (up 51% from FY 2021). Net income: ₩18.0b (up 443% from FY 2021). Profit margin: 7.2% (up from 2.0% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 7.3%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.Major Estimate Revision • Jan 21Consensus EPS estimates increase by 11%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from ₩224.2m to ₩227.7m. EPS estimate increased from ₩769 to ₩854 per share. Net income forecast to grow 135% next year vs 30% growth forecast for Life Sciences industry in South Korea. Consensus price target down from ₩125,455 to ₩122,727. Share price fell 3.6% to ₩82,000 over the past week.Upcoming Dividend • Dec 21Upcoming dividend of ₩500 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. Payout ratio is on the higher end at 85% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (0.7%).Price Target Changed • Nov 18Price target decreased to ₩127,000Down from ₩137,778, the current price target is an average from 10 analysts. New target price is 55% above last closing price of ₩81,900. Stock is down 9.9% over the past year. The company is forecast to post earnings per share of ₩941 for next year compared to ₩177 last year.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Buying Opportunity • Aug 23Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 3.2%. The fair value is estimated to be ₩122,846, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 85% in 2 years. Earnings is forecast to grow by 201% in the next 2 years.Major Estimate Revision • Aug 13Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from ₩221.6m to ₩229.1m. EPS estimate fell from ₩717 to ₩584 per share. Net income forecast to grow 48% next year vs 35% growth forecast for Life Sciences industry in South Korea. Consensus price target broadly unchanged at ₩142,143. Share price fell 3.3% to ₩110,000 over the past week.Major Estimate Revision • Jul 09Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate increased from ₩606 to ₩717. Revenue forecast steady at ₩220.8m. Net income forecast to grow 70% next year vs 36% growth forecast for Life Sciences industry in South Korea. Consensus price target of ₩153,750 unchanged from last update. Share price rose 9.2% to ₩95,100 over the past week.Price Target Changed • Apr 27Price target increased to ₩155,000Up from ₩110,000, the current price target is an average from 4 analysts. New target price is 62% above last closing price of ₩95,800. Stock is down 23% over the past year. The company is forecast to post earnings per share of ₩760 for next year compared to ₩177 last year.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Mar 19Full year 2020 earnings released: ₩651 loss per share (vs ₩993 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: ₩124.1b (up 33% from FY 2019). Net loss: ₩12.1b (loss narrowed 34% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 94% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.分析記事 • Mar 16Investors Who Bought ST PharmLtd (KOSDAQ:237690) Shares A Year Ago Are Now Up 221%It hasn't been the best quarter for ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) shareholders, since the share price has fallen...Is New 90 Day High Low • Mar 05New 90-day low: ₩73,900The company is down 30% from its price of ₩105,500 on 04 December 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 9.0% over the same period.お知らせ • Feb 20ST Pharm Co.,Ltd., Annual General Meeting, Mar 23, 2021ST Pharm Co.,Ltd., Annual General Meeting, Mar 23, 2021, at 09:00 Korea Standard Time.分析記事 • Jan 22Calculating The Fair Value Of ST Pharm Co.,Ltd. (KOSDAQ:237690)Today we will run through one way of estimating the intrinsic value of ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) by taking...お知らせ • Jan 22ST Pharm Co.,Ltd. to Report Q4, 2020 Results on Jan 25, 2021ST Pharm Co.,Ltd. announced that they will report Q4, 2020 results on Jan 25, 2021分析記事 • Dec 23What Type Of Shareholders Own The Most Number of ST Pharm Co.,Ltd. (KOSDAQ:237690) Shares?A look at the shareholders of ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) can tell us which group is most powerful...お知らせ • Dec 13ST Pharm Co.,Ltd. announced that it has received KRW 110 billion in fundingOn December 11, 2020, ST Pharm Co.,Ltd. (KOSDAQ:A237690) closed the transaction.分析記事 • Nov 26Health Check: How Prudently Does ST PharmLtd (KOSDAQ:237690) Use Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...決済の安定と成長配当データの取得安定した配当: A237690はKR市場で注目すべき配当金を支払っていないため、支払いが安定しているかどうかを確認する必要はありません。増加する配当: A237690はKR市場で注目すべき配当金を支払っていないため、支払額が増加しているかどうかを確認する必要はありません。配当利回り対市場ST PharmLtd 配当利回り対市場A237690 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (A237690)0.4%市場下位25% (KR)1.4%市場トップ25% (KR)4.4%業界平均 (Pharmaceuticals)1.1%アナリスト予想 (A237690) (最長3年)0.4%注目すべき配当: A237690の配当金 ( 0.4% ) はKR市場の配当金支払者の下位 25% ( 1.4% ) と比べると目立ったものではありません。高配当: A237690の配当金 ( 0.4% ) はKR市場の配当金支払者の上位 25% ( 4.38% ) と比較すると低いです。株主への利益配当収益カバレッジ: A237690 KR市場において目立った配当金を支払っていません。株主配当金キャッシュフローカバレッジ: A237690 KR市場において目立った配当金を支払っていません。高配当企業の発掘7D1Y7D1Y7D1YKR 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/17 10:39終値2026/07/16 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ST Pharm Co.,Ltd. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12 アナリスト機関Jisoo LeeDAOL Investment & Securities Co., Ltd.Myung Sun LeeDB Financial Investment Co. Ltd.Haesoon KwonEugene Investment & Securities Co Ltd.9 その他のアナリストを表示
Upcoming Dividend • Mar 23Upcoming dividend of ₩500 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 20 April 2026. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (0.6%).
お知らせ • Feb 27ST Pharm Co.,Ltd. announces Annual dividend, payable on April 20, 2026ST Pharm Co.,Ltd. announced Annual dividend of KRW 500.0000 per share payable on April 20, 2026, ex-date on March 30, 2026 and record date on March 31, 2026.
Upcoming Dividend • Dec 20Upcoming dividend of ₩500 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 24 April 2025. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.1%).
Upcoming Dividend • Dec 20Upcoming dividend of ₩500 per share at 0.8% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 29 April 2024. Payout ratio is on the higher end at 81% but the company is not cash flow positive. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.5%). In line with average of industry peers (0.9%).
Upcoming Dividend • Dec 21Upcoming dividend of ₩500 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. Payout ratio is on the higher end at 85% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (0.7%).
分析記事 • Jul 10Should You Be Adding ST PharmLtd (KOSDAQ:237690) To Your Watchlist Today?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Valuation Update With 7 Day Price Move • Jun 08Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩109,500, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩167,043 per share.
Buy Or Sell Opportunity • May 28Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to ₩135,400. The fair value is estimated to be ₩173,672, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.9% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings are also forecast to grow by 26% per annum over the same time period.
Valuation Update With 7 Day Price Move • May 15Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩131,400, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 57% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩138,802 per share.
Major Estimate Revision • Apr 29Consensus EPS estimates increase by 15%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩411.9m to ₩416.9m. EPS estimate increased from ₩3,054 to ₩3,508 per share. Net income forecast to grow 43% next year vs 8.3% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target up from ₩168,249 to ₩183,333. Share price rose 15% to ₩163,400 over the past week.
Price Target Changed • Apr 28Price target increased by 9.0% to ₩175,556Up from ₩161,111, the current price target is an average from 9 analysts. New target price is approximately in line with last closing price of ₩168,700. Stock is up 116% over the past year. The company is forecast to post earnings per share of ₩3,508 for next year compared to ₩2,706 last year.
Valuation Update With 7 Day Price Move • Apr 27Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩167,500, the stock trades at a forward P/E ratio of 55x. Average forward P/E is 21x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 116% over the past three years.
お知らせ • Apr 23ST Pharm Co.,Ltd. to Report Q1, 2026 Results on Apr 27, 2026ST Pharm Co.,Ltd. announced that they will report Q1, 2026 results on Apr 27, 2026
Buy Or Sell Opportunity • Apr 06Now 21% undervaluedOver the last 90 days, the stock has risen 8.2% to ₩136,800. The fair value is estimated to be ₩172,076, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.9% over the last 3 years. Earnings per share has grown by 34%. Revenue is forecast to grow by 48% in 2 years. Earnings are forecast to grow by 60% in the next 2 years.
分析記事 • Mar 27ST PharmLtd's (KOSDAQ:237690) Earnings Are Of Questionable QualityST Pharm Co.,Ltd. ( KOSDAQ:237690 ) announced strong profits, but the stock was stagnant. Our analysis suggests that...
Upcoming Dividend • Mar 23Upcoming dividend of ₩500 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 20 April 2026. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (0.6%).
Buy Or Sell Opportunity • Mar 04Now 24% undervaluedOver the last 90 days, the stock has risen 12% to ₩131,500. The fair value is estimated to be ₩172,330, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.3% over the last 3 years. Earnings per share has grown by 31%. Revenue is forecast to grow by 47% in 2 years. Earnings are forecast to grow by 122% in the next 2 years.
お知らせ • Feb 28ST Pharm Co.,Ltd., Annual General Meeting, Mar 26, 2026ST Pharm Co.,Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 171, haean-ro, danwon-gu, gyeonggi-do, ansan South Korea
お知らせ • Feb 27ST Pharm Co.,Ltd. announces Annual dividend, payable on April 20, 2026ST Pharm Co.,Ltd. announced Annual dividend of KRW 500.0000 per share payable on April 20, 2026, ex-date on March 30, 2026 and record date on March 31, 2026.
Price Target Changed • Feb 14Price target increased by 9.8% to ₩157,000Up from ₩143,000, the current price target is an average from 10 analysts. New target price is 7.0% above last closing price of ₩146,700. Stock is up 74% over the past year. The company is forecast to post earnings per share of ₩2,523 for next year compared to ₩1,780 last year.
Price Target Changed • Feb 10Price target increased by 8.8% to ₩149,000Up from ₩137,000, the current price target is an average from 10 analysts. New target price is approximately in line with last closing price of ₩152,400. Stock is up 70% over the past year. The company is forecast to post earnings per share of ₩2,523 for next year compared to ₩1,780 last year.
お知らせ • Feb 06ST Pharm Co.,Ltd. to Report Fiscal Year 2025 Results on Feb 09, 2026ST Pharm Co.,Ltd. announced that they will report fiscal year 2025 results at 3:30 PM, Korea Standard Time on Feb 09, 2026
分析記事 • Feb 02ST Pharm Co.,Ltd. (KOSDAQ:237690) Stocks Shoot Up 39% But Its P/S Still Looks ReasonableST Pharm Co.,Ltd. ( KOSDAQ:237690 ) shares have continued their recent momentum with a 39% gain in the last month...
Price Target Changed • Jan 26Price target increased by 10% to ₩143,000Up from ₩129,500, the current price target is an average from 10 analysts. New target price is approximately in line with last closing price of ₩149,500. Stock is up 71% over the past year. The company is forecast to post earnings per share of ₩2,523 for next year compared to ₩1,780 last year.
分析記事 • Jan 24ST PharmLtd (KOSDAQ:237690) Seems To Use Debt Quite SensiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Buy Or Sell Opportunity • Jan 21Now 23% undervaluedOver the last 90 days, the stock has risen 29% to ₩116,900. The fair value is estimated to be ₩152,430, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.3% over the last 3 years. Earnings per share has grown by 31%. Revenue is forecast to grow by 49% in 2 years. Earnings are forecast to grow by 137% in the next 2 years.
分析記事 • Dec 30Is There An Opportunity With ST Pharm Co.,Ltd.'s (KOSDAQ:237690) 22% Undervaluation?Key Insights The projected fair value for ST PharmLtd is ₩152,430 based on 2 Stage Free Cash Flow to Equity ST PharmLtd...
Buy Or Sell Opportunity • Dec 26Now 21% undervaluedOver the last 90 days, the stock has risen 36% to ₩120,900. The fair value is estimated to be ₩152,430, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.3% over the last 3 years. Earnings per share has grown by 31%. Revenue is forecast to grow by 49% in 2 years. Earnings are forecast to grow by 137% in the next 2 years.
分析記事 • Dec 15Earnings Tell The Story For ST Pharm Co.,Ltd. (KOSDAQ:237690) As Its Stock Soars 27%ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) shares have continued their recent momentum with a 27% gain in the last month...
Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩117,000, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 57% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩149,224 per share.
Price Target Changed • Nov 22Price target increased by 8.2% to ₩126,500Up from ₩116,889, the current price target is an average from 10 analysts. New target price is 27% above last closing price of ₩99,800. Stock is up 20% over the past year. The company is forecast to post earnings per share of ₩2,444 for next year compared to ₩1,780 last year.
分析記事 • Oct 29ST Pharm Co.,Ltd.'s (KOSDAQ:237690) Share Price Matching Investor OpinionWhen close to half the companies in Korea have price-to-earnings ratios (or "P/E's") below 14x, you may consider ST...
お知らせ • Oct 27ST Pharm Co.,Ltd. to Report Nine Months, 2025 Results on Oct 29, 2025ST Pharm Co.,Ltd. announced that they will report nine months, 2025 results on Oct 29, 2025
分析記事 • Sep 11A Look At The Fair Value Of ST Pharm Co.,Ltd. (KOSDAQ:237690)Key Insights ST PharmLtd's estimated fair value is ₩81,102 based on 2 Stage Free Cash Flow to Equity With ₩93,700 share...
Buy Or Sell Opportunity • Sep 03Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 28% to ₩98,700. The fair value is estimated to be ₩81,102, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 36%. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 110% in the next 2 years.
分析記事 • Aug 26Is ST PharmLtd (KOSDAQ:237690) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Aug 05Here's Why ST PharmLtd (KOSDAQ:237690) Has Caught The Eye Of InvestorsKOSDAQ:A237690 1 Year Share Price vs Fair Value Explore ST PharmLtd's Fair Values from the Community and select yours...
Buy Or Sell Opportunity • Jul 22Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 23% to ₩94,300. The fair value is estimated to be ₩77,818, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 89% in the next 2 years.
お知らせ • Jul 18ST Pharm Co.,Ltd. to Report First Half, 2025 Final Results on Jul 24, 2025ST Pharm Co.,Ltd. announced that they will report first half, 2025 final results on Jul 24, 2025
Buy Or Sell Opportunity • Jul 01Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 16% to ₩84,400. The fair value is estimated to be ₩68,902, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 52% in 2 years. Earnings are forecast to grow by 89% in the next 2 years.
分析記事 • Jun 13Shareholders Should Be Pleased With ST Pharm Co.,Ltd.'s (KOSDAQ:237690) PriceST Pharm Co.,Ltd.'s ( KOSDAQ:237690 ) price-to-earnings (or "P/E") ratio of 55.4x might make it look like a strong sell...
Buy Or Sell Opportunity • Jun 09Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 9.5% to ₩80,300. The fair value is estimated to be ₩66,340, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 52% in 2 years. Earnings are forecast to grow by 89% in the next 2 years.
分析記事 • May 26ST PharmLtd (KOSDAQ:237690) Takes On Some Risk With Its Use Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • May 07Calculating The Intrinsic Value Of ST Pharm Co.,Ltd. (KOSDAQ:237690)Key Insights ST PharmLtd's estimated fair value is ₩66,531 based on 2 Stage Free Cash Flow to Equity Current share...
Buy Or Sell Opportunity • Apr 29Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to ₩78,200. The fair value is estimated to be ₩98,270, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 46%. For the next 3 years, revenue is forecast to grow by 20% per annum. Earnings are also forecast to grow by 27% per annum over the same time period.
お知らせ • Apr 28ST Pharm Co.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025ST Pharm Co.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩77,500, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 15x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 17% over the past three years.
分析記事 • Apr 02ST PharmLtd's (KOSDAQ:237690) Earnings Are Built On Soft FoundationsSolid profit numbers didn't seem to be enough to please ST Pharm Co.,Ltd.'s ( KOSDAQ:237690 ) shareholders. Our...
New Risk • Apr 01New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 35% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.
お知らせ • Mar 01ST Pharm Co.,Ltd., Annual General Meeting, Mar 31, 2025ST Pharm Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 171, haean-ro, danwon-gu, gyeonggi-do, ansan South Korea
Major Estimate Revision • Feb 12Consensus EPS estimates fall by 23%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from ₩362.2m to ₩329.5m. EPS estimate also fell from ₩2,579 per share to ₩1,975 per share. Net income forecast to grow 24% next year vs 6.1% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩127,700 unchanged from last update. Share price rose 3.6% to ₩85,800 over the past week.
分析記事 • Feb 11Getting In Cheap On ST Pharm Co.,Ltd. (KOSDAQ:237690) Might Be DifficultWith a price-to-earnings (or "P/E") ratio of 58.1x ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) may be sending very bearish...
Valuation Update With 7 Day Price Move • Feb 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩93,400, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 20x in the Pharmaceuticals industry in South Korea. Negligible returns to shareholders over past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩41,024 per share.
お知らせ • Feb 06ST Pharm Co.,Ltd. to Report Q4, 2024 Results on Feb 10, 2025ST Pharm Co.,Ltd. announced that they will report Q4, 2024 results on Feb 10, 2025
分析記事 • Jan 21Does ST PharmLtd (KOSDAQ:237690) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Upcoming Dividend • Dec 20Upcoming dividend of ₩500 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 24 April 2025. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.1%).
Valuation Update With 7 Day Price Move • Dec 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩75,600, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 14x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 39% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩61,471 per share.
分析記事 • Nov 22Should You Be Adding ST PharmLtd (KOSDAQ:237690) To Your Watchlist Today?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Major Estimate Revision • Nov 05Consensus EPS estimates fall by 14%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩300.6m to ₩296.6m. EPS estimate also fell from ₩2,058 per share to ₩1,769 per share. Net income forecast to grow 100% next year vs 13% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩127,700 unchanged from last update. Share price rose 3.1% to ₩97,600 over the past week.
分析記事 • Aug 30ST Pharm Co.,Ltd.'s (KOSDAQ:237690) Shares Climb 29% But Its Business Is Yet to Catch UpThe ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) share price has done very well over the last month, posting an excellent gain...
Major Estimate Revision • Aug 20Consensus EPS estimates increase by 17%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from ₩296.6m to ₩311.4m. EPS estimate increased from ₩1,912 to ₩2,236 per share. Net income forecast to grow 101% next year vs 16% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target up from ₩115,778 to ₩119,111. Share price rose 12% to ₩100,300 over the past week.
分析記事 • Aug 17Is Now The Time To Put ST PharmLtd (KOSDAQ:237690) On Your Watchlist?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩74,200, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 16x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 32% over the past three years.
お知らせ • Jul 23ST Pharm Co.,Ltd. to Report Q2, 2024 Results on Jul 25, 2024ST Pharm Co.,Ltd. announced that they will report Q2, 2024 results on Jul 25, 2024
New Risk • May 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Large one-off items impacting financial results.
分析記事 • May 09Is ST Pharm Co.,Ltd. (KOSDAQ:237690) Trading At A 41% Discount?Key Insights ST PharmLtd's estimated fair value is ₩157,784 based on 2 Stage Free Cash Flow to Equity Current share...
Buy Or Sell Opportunity • May 02Now 23% undervaluedOver the last 90 days, the stock has risen 45% to ₩88,800. The fair value is estimated to be ₩114,797, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 29% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 40% per annum over the same time period.
お知らせ • May 01ST Pharm Co.,Ltd. to Report Q1, 2024 Results on May 02, 2024ST Pharm Co.,Ltd. announced that they will report Q1, 2024 results on May 02, 2024
分析記事 • Mar 22Why ST PharmLtd's (KOSDAQ:237690) Earnings Are Better Than They SeemST Pharm Co.,Ltd. ( KOSDAQ:237690 ) announced a healthy earnings result recently, and the market rewarded it with a...
Reported Earnings • Mar 20Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: EPS: ₩1,041 (up from ₩957 in FY 2022). Revenue: ₩285.0b (up 14% from FY 2022). Net income: ₩19.6b (up 8.8% from FY 2022). Profit margin: 6.9% (down from 7.2% in FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 14%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
分析記事 • Mar 18ST Pharm Co.,Ltd. (KOSDAQ:237690) Stock Rockets 54% As Investors Are Less Pessimistic Than ExpectedThe ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) share price has done very well over the last month, posting an excellent gain...
お知らせ • Feb 28ST Pharm Co.,Ltd., Annual General Meeting, Mar 25, 2024ST Pharm Co.,Ltd., Annual General Meeting, Mar 25, 2024, at 09:01 Korea Standard Time. Location: 3F ST Pharm Banwol Campus Innovation Center (171, Haean- ro, Danwon-gu, Ansan-si, Gyeonggi-do) South Korea Agenda: To consider approval of the 16th (consolidated) financial statements, cash dividend of KRW 500 per share; to consider appointment of director; to consider appointment of auditor and to consider other matters.
Buy Or Sell Opportunity • Feb 27Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at ₩63,800. The fair value is estimated to be ₩81,265, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 365% in the next 2 years.
Major Estimate Revision • Feb 03Consensus EPS estimates increase by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from ₩312.7m to ₩322.1m. EPS estimate increased from ₩1,837 to ₩2,044 per share. Net income forecast to grow 199% next year vs 27% growth forecast for Life Sciences industry in South Korea. Consensus price target of ₩105,000 unchanged from last update. Share price was steady at ₩61,200 over the past week.
お知らせ • Feb 01ST Pharm Co.,Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024ST Pharm Co.,Ltd. announced that they will report fiscal year 2023 results on Feb 01, 2024
Upcoming Dividend • Dec 20Upcoming dividend of ₩500 per share at 0.8% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 29 April 2024. Payout ratio is on the higher end at 81% but the company is not cash flow positive. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.5%). In line with average of industry peers (0.9%).
Major Estimate Revision • Nov 07Consensus EPS estimates fall by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩291.5m to ₩284.2m. EPS estimate also fell from ₩1,376 per share to ₩1,206 per share. Net income forecast to grow 62% next year vs 23% growth forecast for Life Sciences industry in South Korea. Consensus price target down from ₩121,000 to ₩111,818. Share price rose 4.7% to ₩71,200 over the past week.
お知らせ • Aug 11ST Pharm Co.,Ltd. announced that it has received KRW 100 billion in fundingOn August 9, 2023, ST Pharm Co.,Ltd. closed the transaction.
Reported Earnings • Mar 23Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: ₩957 (up from ₩177 in FY 2021). Revenue: ₩249.3b (up 51% from FY 2021). Net income: ₩18.0b (up 443% from FY 2021). Profit margin: 7.2% (up from 2.0% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 7.3%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.
Major Estimate Revision • Jan 21Consensus EPS estimates increase by 11%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from ₩224.2m to ₩227.7m. EPS estimate increased from ₩769 to ₩854 per share. Net income forecast to grow 135% next year vs 30% growth forecast for Life Sciences industry in South Korea. Consensus price target down from ₩125,455 to ₩122,727. Share price fell 3.6% to ₩82,000 over the past week.
Upcoming Dividend • Dec 21Upcoming dividend of ₩500 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. Payout ratio is on the higher end at 85% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (0.7%).
Price Target Changed • Nov 18Price target decreased to ₩127,000Down from ₩137,778, the current price target is an average from 10 analysts. New target price is 55% above last closing price of ₩81,900. Stock is down 9.9% over the past year. The company is forecast to post earnings per share of ₩941 for next year compared to ₩177 last year.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Buying Opportunity • Aug 23Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 3.2%. The fair value is estimated to be ₩122,846, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 85% in 2 years. Earnings is forecast to grow by 201% in the next 2 years.
Major Estimate Revision • Aug 13Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from ₩221.6m to ₩229.1m. EPS estimate fell from ₩717 to ₩584 per share. Net income forecast to grow 48% next year vs 35% growth forecast for Life Sciences industry in South Korea. Consensus price target broadly unchanged at ₩142,143. Share price fell 3.3% to ₩110,000 over the past week.
Major Estimate Revision • Jul 09Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate increased from ₩606 to ₩717. Revenue forecast steady at ₩220.8m. Net income forecast to grow 70% next year vs 36% growth forecast for Life Sciences industry in South Korea. Consensus price target of ₩153,750 unchanged from last update. Share price rose 9.2% to ₩95,100 over the past week.
Price Target Changed • Apr 27Price target increased to ₩155,000Up from ₩110,000, the current price target is an average from 4 analysts. New target price is 62% above last closing price of ₩95,800. Stock is down 23% over the past year. The company is forecast to post earnings per share of ₩760 for next year compared to ₩177 last year.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 19Full year 2020 earnings released: ₩651 loss per share (vs ₩993 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: ₩124.1b (up 33% from FY 2019). Net loss: ₩12.1b (loss narrowed 34% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 94% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.
分析記事 • Mar 16Investors Who Bought ST PharmLtd (KOSDAQ:237690) Shares A Year Ago Are Now Up 221%It hasn't been the best quarter for ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) shareholders, since the share price has fallen...
Is New 90 Day High Low • Mar 05New 90-day low: ₩73,900The company is down 30% from its price of ₩105,500 on 04 December 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 9.0% over the same period.
お知らせ • Feb 20ST Pharm Co.,Ltd., Annual General Meeting, Mar 23, 2021ST Pharm Co.,Ltd., Annual General Meeting, Mar 23, 2021, at 09:00 Korea Standard Time.
分析記事 • Jan 22Calculating The Fair Value Of ST Pharm Co.,Ltd. (KOSDAQ:237690)Today we will run through one way of estimating the intrinsic value of ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) by taking...
お知らせ • Jan 22ST Pharm Co.,Ltd. to Report Q4, 2020 Results on Jan 25, 2021ST Pharm Co.,Ltd. announced that they will report Q4, 2020 results on Jan 25, 2021
分析記事 • Dec 23What Type Of Shareholders Own The Most Number of ST Pharm Co.,Ltd. (KOSDAQ:237690) Shares?A look at the shareholders of ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) can tell us which group is most powerful...
お知らせ • Dec 13ST Pharm Co.,Ltd. announced that it has received KRW 110 billion in fundingOn December 11, 2020, ST Pharm Co.,Ltd. (KOSDAQ:A237690) closed the transaction.
分析記事 • Nov 26Health Check: How Prudently Does ST PharmLtd (KOSDAQ:237690) Use Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...